Literature DB >> 10718555

Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin.

C Westbury1, L Vini, C Fisher, C Harmer.   

Abstract

Thyroglobulin (Tg) is a reliable tumor marker in patients with well-differentiated thyroid cancer (WDTC). We identified 11 patients who had undetectable serum Tg and no thyroglobulin antibody (TgAb) in the presence of clinical disease. Three had residual disease after ablation of the thyroid by surgery plus radioiodine and 8 relapsed after a disease-free interval. Histologic review confirmed that 7 of the tumors were papillary carcinomas and 4 were follicular carcinomas. Immunohistochemical staining for Tg was positive in 6 of 7 papillary and in 3 of 4 follicular carcinomas. There were no identifiable histologic or clinical features that could be used to predict further patients who may relapse with absence of this serum marker. Negative serum Tg did not appear to be an adverse prognostic feature. During follow-up, measurement of Tg and TgAb should be supplemented by radioiodine scanning and radiological imaging in patients in whom recurrence is likely or suspected.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10718555     DOI: 10.1089/thy.2000.10.171

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  10 in total

1.  Preoperative determination of serum thyroglobulin to identify patients with differentiated thyroid cancer who may present recurrence without increased thyroglobulin.

Authors:  B Gibelli; P Tredici; C De Cicco; L Bodei; M T Sandri; G Renne; R Bruschini; N Tradati
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-04       Impact factor: 2.124

2.  Location of functioning metastases from differentiated thyroid carcinoma by simultaneous double isotope acquisition of I-131 whole body scan and bone scan.

Authors:  C Ceccarelli; F Bianchi; D Trippi; F Brozzi; F Di Martino; P Santini; R Elisei; A Pinchera
Journal:  J Endocrinol Invest       Date:  2004-10       Impact factor: 4.256

3.  Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma.

Authors:  A Golger; T R Fridman; S Eski; I J Witterick; J L Freeman; P G Walfish
Journal:  J Endocrinol Invest       Date:  2003-10       Impact factor: 4.256

4.  Detection of metastases from differentiated thyroid cancer by different imaging techniques (neck ultrasound, computed tomography and [18F]-FDG positron emission tomography) in patients with negative post-therapeutic ¹³¹I whole-body scan and detectable serum thyroglobulin levels.

Authors:  Laura Agate; Francesca Bianchi; A Giorgetti; P Sbragia; V Bottici; F Brozzi; P Santini; E Molinaro; P Vitti; R Elisei; C Ceccarelli
Journal:  J Endocrinol Invest       Date:  2014-07-29       Impact factor: 4.256

5.  Recombinant TSH stimulated remnant ablation therapy in thyroid cancer: the success rate depends on the definition of ablation success--an observational study.

Authors:  Anouk N A van der Horst-Schrivers; Wim J Sluiter; Anneke C Muller Kobold; Bruce H R Wolffenbuttel; John T M Plukker; Peter H Bisschop; John M de Klerk; Imad Al Younis; Paul Lips; Jan W Smit; Adrienne H Brouwers; Thera P Links
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

6.  Clinical laboratory verification of thyroglobulin concentrations in the presence of autoantibodies to thyroglobulin: comparison of EIA, radioimmunoassay and LC MS/MS measurements in an Urban Hospital.

Authors:  Sarah E Wheeler; Li Liu; Harry C Blair; Richard Sivak; Nancy Longo; Jeffery Tischler; Kathryn Mulvey; Octavia M Peck Palmer
Journal:  BMC Res Notes       Date:  2017-12-08

7.  Utility of Stimulated Thyroglobulin in Reclassifying Low Risk Thyroid Cancer Patients' Following Thyroidectomy and Radioactive Iodine Ablation: A 7-Year Prospective Trial.

Authors:  Anwar A Jammah; Afshan Masood; Layan A Akkielah; Shaimaa Alhaddad; Maath A Alhaddad; Mariam Alharbi; Abdullah Alguwaihes; Saad Alzahrani
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-24       Impact factor: 5.555

8.  Lung nodule detected by F-18 fluorodeoxyglucose positron emission tomography-computed tomography in patients with papillary thyroid cancer, negative 131I whole body scan, and undetectable serum-stimulated thyroglobulin levels: two case reports.

Authors:  Chan-Hee Jung; Hyeon-Jeong Goong; Bo-Yeon Kim; Jung-Mi Park; Jeong-Ja Kwak; Chul-Hee Kim; Hyun-Sook Hong; Sung-Koo Kang; Ji-Oh Mok
Journal:  J Med Case Rep       Date:  2012-10-31

Review 9.  Use of thyroglobulin as a tumour marker.

Authors:  Buddhike Sri Harsha Indrasena
Journal:  World J Biol Chem       Date:  2017-02-26

10.  Added Value of Postoperative Radioiodine Scan for Staging and Risk Stratification in Papillary Thyroid Microcarcinoma.

Authors:  Tawika Kaewchur; Sirianong Namwongprom; Nipawan Waisayanand; Waralee Pongwiwattanachai; Molrudee Ekmahachai
Journal:  J ASEAN Fed Endocr Soc       Date:  2021-04-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.